chrisvoncsefalvay/vaers-outcomes huggingface dataset:
she took the vaccine because it said it would work well for the skin; psoriasis; thinner skin; more sensitivity to tearing and with her psoriasis problem she has skin tears that would not closing and were open wounds; more sensitivity to tearing and with her psoriasis problem she has skin tears that would not closing and were open wounds; Headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 48 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation, psoriasis. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: OFF LABEL USE (non-serious), outcome "unknown", described as "she took the vaccine because it said it would work well for the skin"; PSORIASIS (non-serious), outcome "unknown", described as "psoriasis"; SKIN ATROPHY (non-serious), outcome "unknown", described as "thinner skin"; SKIN LACERATION (non-serious), IMPAIRED HEALING (non-serious), outcome "unknown" and all described as "more sensitivity to tearing and with her psoriasis problem she has skin tears that would not closing and were open wounds"; HEADACHE (non-serious), outcome "unknown", described as "Headache".  Additional information: It was confirmed that Covid 19 BioNtech vaccine was a Pfizer product. She said that her skin got thinner skin and more sensitivity to tearing and with her psoriasis problem she has skin tears that would not closing and were open wounds. It was reported that patient was riding her scooter she was healthier than the average women, and reporter was surprised when she saw she had psoriasis that showed on the arm, it was because of this vaccine. It was reported that patient had thinner skin and skin tears that would not heal. Reporter was stating that it was unethical for a product to be marketed as a skin treatment because people that had skin conditions can have side effects. Reporter could not provide the website where she got some of her information about the vaccine being used to improve skin conditions. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
w/in 5hr p/vax pt became fussy, refused to nurse & devel high pitched, inconsolable screaming for over an hour;mom stated baby's head went back & arm & legs were extended & remained like this for awhile;contracted spinal meningitis
Patient was given vaccines in AM and later in evening developed fever to 104.9.  Also had some abnormal "twitching" of body that was able to be suppresed with pressure
Red welt around area of SHOT. Little blisters that were seeping clear liquid around shot area. Hot to touch. 10.25inx8.5in (outside) 2inx1.75in (inside)
Patient received Zostavax 10/3/07.  On 10/6/07 developed back pain by 10/9/07 rash upper left side along dermatones T6T4.  Seen in ER with f/u MD office visit.  Received Valtrex, Percocet.
Syncope after injection.  Vital signs monitored for 30 min, pt stable.  No other reactions noted.
This spontaneous report was received from a Licensed Practical Nurse and refers to a 19 year old patient of unknown gender. No pertinent medical history, drug reactions or allergies were reported. On 09-JUN-2017, the patient was vaccinated with a pediatric dose of VAQTA for prophylaxis (dose, route of administration, anatomical location, lot number and expiration date were not reported). No adverse  effects were reported.
Polymyalgia Rheumatica; Symptoms for polymyalgia rheumatica were intensely painful; Initial information received on 28-Oct-2021 regarding an unsolicited valid serious case received from a non-healthcare professional (under the reference number: US-SA-SAC20211102000455).  This case involves a female patient who experienced polymyalgia rheumatica, symptoms for polymyalgia rheumatica were intensely painful (pain) when received vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  On 02-OCT-2018, patient had past vaccination FLUZONE HIGH DOSE with (first dose: lot number: UJ030AA, expiry date: 05-MAY-2019, route: intramuscular, site: left deltoid) for prophylactic vaccination.  On 05-SEP-2019, patient had past vaccination FLUZONE HIGH DOSE with (second dose: lot number: UJ232AB, expiry date: 10-APR-2020, route: intramuscular, site: left deltoid) for prophylactic vaccination.  On 03-MAR-2021, patient had past vaccination with COVID-19 VACCINE MODERNA for prophylactic vaccination.  Patient had additional anxiety over COVID-19 VACCINE MODERNA.  The patient's medical history, past concomitant medication and family history were not provided.  On 01-Sep-2021, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (suspension for injection, lot number: UJ715AA and expiry date: 30-JUN-2022) via an intramuscular route in the left deltoid for prophylactic vaccination.  On an unknown date the patient developed a serious polymyalgia rheumatica (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. This event was assessed as medically significant.  On 28-SEP-2021 the patient developed a serious symptoms for polymyalgia rheumatica which were intensely painful (pain) (twenty seven days) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. This event was assessed as medically significant.  Laboratory details were not reported.  The patient was treated with PREDNISONE for polymyalgia rheumatica and pain.  Patient's General Practitioner (GP) had put her on 20 mg of Prednisone per day and had referred her to a Rheumatologist. This was definitely a miracle drug as using it correctly and daily she was without pain. Prednisone is an immunosuppressant.  At the time of reporting, the outcome was unknown for the events (polymyalgia rheumatica, pain).; Sender's Comments: This case concerns a female patient who experienced polymyalgia rheumatica (unknown latency), pain (twenty-seven days) after vaccination with FLUZONE HIGH-DOSE QUADRIVALENT. The time to onset is unknown for polymyalgia rheumatica and compatible for pain. Past vaccination included FLUZONE HIGH DOSE and COVID-19 VACCINE MODERNA. The patient was treated with PREDNISONE. There is no further information regarding patient's medical condition at the time of vaccination and laboratory tests ruling out other alternate etiologies were not reported. Based upon the reported information, the role of the individual suspect vaccine cannot be assessed.
SHINGRIX 50mcg inj first shot. I never had a reaction to any shot before. My arm was very sore and is still hurting, 4 days later. I think the diarrhea was like nothing I have ever experienced. It started with terrible cramps. Then like pure water for over 90 minutes and every 5 hours later. The second day I saw bright red blood in my stool. I was concerned the printout I was given listed this over 1/2 way down. When it started without a warning on the third day I was not home and it started once and again after 45 minutes and then after 30 minutes the first spill.
Went to ED c/o body felt "on fire" after receiving vaccine - C/o chest pain at 1 hour after arriving in ED - mild swelling (L) deltoid - No redness/no rash - No acute distress - No SOB - Rec'd XANAX and TYLENOL
Definite decrease in exercise tolerance as well as strength. I go to the gym most days of the week, alternating between strength training and aerobics (stationary bicycle). I am currently stationed in Texas, and was in Korea for one month only. After having been there for a week, and several trips to the gym, I had my smallpox vaccination. About a week after the vaccination, I noticed that I had a definite decrease in my strength when lifting weights as well as a decrease in my exercise tolerance on the stationary bike. This was using the same free weights and machines that I had previously used after my arrival in Korea.  Upon returning to Texas, I continue to have decreased strength (e.g. I was using a 30# dumbbell before to do 15 bicep curls, 2 sets for each arm. Since the vaccination, I can barely do the first set and can only do 3-5 of the second set without the assistance of the other arm). My aerobic exercise has improved faster, but is still affected.
This spontaneous report as received from a pharmacist refers to an adult patient of unknown age. Medical history and concurrent conditions were not reported. In March 2014, reported as last week, the patient was vaccinated with the second dose of RECOMBIVAX HB 5mcg/0.5ml, pediatric formulation (incorrect product formulation administered). Dose, route, lot number and expiration date were not reported. No co-suspect and concomitant therapies were reported. No adverse events were reported. It was confirmed with the reporter that this medication error was not related to label confusion. Additional information has been requested.
Infanrix accidentally given instead of TDaP; This non-serious case was reported by a nurse via call center representative and described the occurrence of wrong vaccine administered in a patient who received DTPa (Infanrix) for prophylaxis.   On 02-MAY-2023, the patient received Infanrix. On 02-MAY-2023, an unknown time after receiving Infanrix, the patient experienced wrong vaccine administered (Verbatim: Infanrix accidentally given instead of TDaP). The outcome of the wrong vaccine administered was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 02-MAY-2023 The reporter called to report that Infanrix was accidentally given instead of TDaP and wished to know how to proceed.  They did not provide information about the patient or vaccine.  The reporter did not consent to follow-up. The reporter called to report that Infanrix was accidentally given instead of TDaP, which led to wrong vaccine administered.
chills; sweat; pain; redness; swelling in the injections site; fever sensation; This is a spontaneous report from a non-contactable consumer, the patient.   A female patient of an unspecified age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown) via an unspecified route of administration on 11Mar2021 as single dose for COVID-19 immunisation.  The patient medical history and concomitant medications were not reported. The patient reported that she was administered with the second dose of the Pfizer's COVID-19 vaccine on Thursday, 11Mar2021 and that night she had chills, sweat, pain, redness and swelling in the injections site. The consumer reported that the redness, swelling and fever sensation continues until today and it has been 4 since the administration of the vaccine. The consumer finished the interaction saying that she was going to contact her physician. The patient had not recovered from the events, redness, swelling and fever sensation. Outcome of the events, chills, sweat, and pain was unknown.   The lot number for the vaccine, BNT162B2, was not provided and has been requested.
Vaccine dose #1 Pfizer 05/25/2021 Lot # EW0178 Cureently has covid 19
Patient received Adacel after excursion to -2C (excursion occurred because of malfunction of older refrigerator); Initial information received on 05-Jul-2019 regarding an unsolicited valid non-serious case received from a other healthcare professional (other-pharmacy) by phone.  This case involves a patient of unknown demographics was vaccinated with a dose of DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE [ADACEL] (Batch number, expiry date, dose, dose in series, route and site of administration were not reported) on an unknown date.  The patient's past medical history, medical treatment(s), vaccination(s), family history and concomitant medications were not provided.   It was a case of actual medication error due to product storage error temperature too low because Patient received Adacel after excursion to -2C (excursion occurred because of malfunction of older refrigerator)  It was unknown if any adverse event occurred or not following the vaccination.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive and Module VI of the Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.   Information on batch number was requested.  Documents held by the sender: none.
The patient presented to the hospital on 04/21/2022 with left lower extremity pain and intermittent chest pain for 1 week. He was diagnosed with left lower extremity deep vein thrombosis and pulmonary embolism of the right pulmonary artery.  His echo was normal. He was treated with apixaban and discharge home within 24 hours.
tested positive on 07Jul2022; tested positive on 07Jul2022; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 50-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 26Feb2021 at 14:00 as dose 1, single (Lot number: En6202), in right arm, on 19Mar2021 at 13:00 as dose 2, single (Lot number: Ep7534), in right arm, on 26Sep2021 at 12:00 as dose 3 (booster), single (Lot number: Fd8448), in right arm and on 26Feb2022 at 12:00 as dose 4 (booster), single (Lot number: Fm0698) at the age of 49 years, in right arm for covid-19 immunisation. The patient's relevant medical history included: "Endometriosis" (unspecified if ongoing); "Migraines" (unspecified if ongoing); "Hypothyroidism" (unspecified if ongoing). There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 07Jul2022, outcome "not recovered" and all described as "tested positive on 07Jul2022". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (07Jul2022) Positive, notes: tested positive on 07Jul2022 and began taking Paxlovid; (11Jul2022) Negative; (12Jul2022) Negative; (23Jul2022) Positive, notes: tested myself again on 23Jul and had two positive tests; (23Jul2022) Positive tests. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Patient had received other medication within 2 weeks. Patient received anti viral for COVID 19 Treatment: Paxlovid. Treatment start date was 07Jul2022 and stop date:11Jul2022. Patient had no known allergies.; Sender's Comments: As there is limited information in the case provided, the causal association between the events Vaccination failure and Covid-19 and the suspect drug cannot be excluded. The case will be reassessed once new information is available.
cellulitis; arm was raised up and swollen from top of arm to elbow; itchy; A spontaneous report  was received from a consumer concerning a 74-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the event(s) Cellulitis, arm was raised up and swollen from top of arm to elbow and itchy.    The patient's medical history  was not provided. Concomitant medication included was also not reported.  On 04 Mar 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot/batch: 002A21A) via unknown route in the left arm for prophylaxis of COVID-19 infection.     On 11 Mar 2021, the patient experienced Cellulitis, arm was raised up and swollen from top of arm to elbow and itchy.   Treatment details included cephalexin.  Action taken with mRNA-1273 in response to the events was unknown.  The outcome of the event(s)Cellulitis, arm was raised up and swollen from top of arm to elbow and itchy were unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Patient 9/2/2009 presented to the vaccination site on 11/9/2021. The client notified RN,  that he received a single dose of Pfizer COVID vaccine on 10/20/21. Client was accompanied by Counselor. Vaccinator informed RN that client was here one day before his second dose due date. RN submitted a medical consult via text message to Vaccine Operations Leads, requesting to proceed with the COVID vaccine Pfizer second dose. Per Dr, approval to proceed with COVID vaccine Pfizer second dose was obtained from medical consult team, vaccine operations lead, RN via text message.  Client received covid vaccine Pfizer LOT # FF8839 on 11/9/2021.The client did not report any symptoms during the 15 minute observation period. RN educated client on possible adverse reactions and when to seek medical care. The client left the vaccination site at 1215. Client left vaccine site with Counselor unassisted and with a steady gait.
Patient with a very large knot under the surface of the skin that would not resolve for quite a few weeks.
Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Systemic: Rash with bumps appeared on both arms-Mild
On 09/15/2000 the patient experienced chickenpox with about 70 lesions and no fever. Medical attention was sought. It was felt that the patient had a "light case" and she recovered. No further information is available.
Already described people - excruciating pain in my right shoulder arm & elbow causing nausea. Shot given in left arm. I?m at home so far nothing dead or hospitalized thank you
He is undergoing stent placement today as a result of an MI; clogged arteries; This is a spontaneous report from a Pfizer sponsored program. A contactable consumer reported for a male patient (brother-in-law). A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number was not reported), via an unspecified route of administration on an unspecified date as dose 2, single and received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number was not reported) via an unspecified route of administration on an unspecified date as dose 1, single both for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient was undergoing stent placement today as a result of an MI and had clogged arteries. The patient was undergoing stent placement today as a result of an MI. He also received both doses of the vaccine, but reporter did not have dates, lot numbers, or his age. The reporter just stated that he was a little bit older than her, and that it does not run in his family. The reporter complained that the covid shot was not a vaccine. If anything, it not only clogged the reporters arteries, but also her brother in law's. The reporter believed the ingredients in the vaccine cause blockages. The reporter asked if the ingredients could have caused her heart attack and if they've been the same all along. Therapeutic measures were taken as a result of the events. The outcome of the events was unknown.  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
I had the most peculiar taste in my mouth. It wasn't entirely a metal taste, but it was strong enough it overwhelmed the taste of everything else for about 6 hours. I could still taste other things, but the primary taste and the one that remained in my mouth was this odd, almost metal taste.  The next day (after the taste was gone)-  it would have been almost 24 hours from the time of the injection - I was hit with a bad headache and body aches like I haven't had in many years. The body ache was gone the next morning, and the headache lingered another day past that. Today, Tuesday March 9, is the first day I feel like myself again.
This case was reported by a other health professional via call center representative and described the occurrence of pruritus in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a day after receiving SHINGRIX, the patient experienced pruritus and erythema urticarial. On an unknown date, the outcome of the pruritus was unknown and the outcome of the erythema urticarial was recovered/resolved. It was unknown if the reporter considered the pruritus and erythema urticarial to be related to SHINGRIX. Additional details reported as follows: This case was reported by the medical assistant (MA). The age at vaccination was not reported. Within 24 hours after vaccination the patient experienced itching and red welts across her abdomen. The red welts lasted for about 90 minutes and completely went away after. The batch number of SHINGRIX was unknown. No further details were provided.
Prolonged diarrhea starting 2 days after immunization and lasting 4-5 weeks.
Reports sensation of heart skipping beat since last night at 11pm into 11am this morning. Also with fever of 100-101. Took advil and tylenol with relief. No further cardiac symptoms since this AM (now 4pm). Also with diarrhea, however thinks this was triggered by spicy food he had. Feeling improved now, no other symptoms. Had HPV vaccine 2 days ago (1 day prior to symptom onset).
severe vomiting starting 12 hours after vaccine for 8 hours.  Nausea has continued for 11 days.  Occasional vomiting. Loss of appetite continues.  Also neck hurts from intensity of vomiting.
She reports around 1409 she started noticing an itchy rash on her bilateral hands.
A report has been received from a health professional concerning a 13 year old, male patient who had been receiving Nasal FLUMIST QUADRIVALENT. FLUMIST QUADRIVALENT (Intranasal) was administered on 17-Jan-2014. The health professional reported administration of expired FLUMIST QUADRIVALENT as expiration date of the drug was 13-JAN-2014. FLUMIST QUADRIVALENT (Intranasal) was discontinued on 17-Jan-2014. The outcome of the event of expired FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious by the reporter.
"Moderna COVID-19 Vaccine EUA" - large rash around the injection site approximately 6-7 inches in diameter. Rash has grown to this size within three days after second injection. Rash is red, hot, itchy, and sore.
This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), HEADACHE (Headache), NAUSEA (Nausea) and CHILLS (Chills) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Feb-2021, the patient experienced DIZZINESS (Dizziness), HEADACHE (Headache), NAUSEA (Nausea) and CHILLS (Chills). At the time of the report, DIZZINESS (Dizziness), HEADACHE (Headache), NAUSEA (Nausea) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication details were provided. No treatment medication details were provided.